Silco Pharmaceuticals Limited (DSE:SILCOPHL)

Market Cap	2.15B +33.5%
Revenue (ttm)	408.71M -4.6%
Net Income	34.23M -26.5%
EPS	0.33 -26.7%
Shares Out	103.81M
PE Ratio	62.56
Forward PE	n/a
Dividend	0.11 (0.51%)
Ex-Dividend Date	Dec 17, 2025

Volume	1,378,014
Open	21.40
Previous Close	21.40
Day's Range	20.50 - 21.60
52-Week Range	11.10 - 23.30
Beta	0.21
Analysts	n/a
Price Target	n/a
Earnings Date	Dec 8, 2026

About Silco Pharmaceuticals

Silco Pharmaceuticals Limited engages in manufacturing, distribution, and marketing of finished pharmaceutical products in Bangladesh. It offers products in the therapeutic areas of analgesic and antipyretic, anti-platelet, antiasthmatic, antibiotic, antidepressant, antidiabetic, antiemetic, antifungal, antihistamin, antihypertensive and antianginal, antimicrobial, antiprotozoal, antispasmodic, antiulcerant, anxiolytic, calcium and combinations, central muscle relaxants, diuretics, gastroprokinetic, haematinic, vitamins and minerals, laxatives,...

• Industry: Pharmaceutical Preparations
• Founded: 1995
• Employees: 313
• Stock Exchange: Dhaka Stock Exchange
• Ticker Symbol: SILCOPHL

Financial Performance

In fiscal year 2025, Silco Pharmaceuticals's revenue was 431.54 million, an increase of 5.23% compared to the previous year's 410.10 million. Earnings were 42.65 million, a decrease of -7.04%.

Data Source: S&P Global Market Intelligence

Fundamental and historical data is provided by S&P Global Market Intelligence.

Last checked:

Jul 26, 2026

Data Sources Report a data error